Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | AGT | P01019 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679199 | 0.89 | AGTR1 (0.47) | LTB4R2AGTR1AGTR2HPGDAGT | |
| SCHEMBL3370402 | 0.87 | AGTR1 (0.46) | LTB4R2AGTR1AGTR2EPHX2HPGD | |
| SCHEMBL4735569 | 0.83 | SOAT1 (0.47) | AGTR1AGTR2HPGDALDH1A1POLB | |
| SCHEMBL9541811 | 0.83 | AGTR1 (0.50) | AGTR1AGTR2AGTHTR1AHTR7 | |
| SCHEMBL9084585 | 0.82 | AGTR1 (0.47) | LTB4R2AGTR1AGTR2AGTHDAC1 | |
| SCHEMBL489527 | 0.82 | AGTR1 (0.49) | AGTR1AGTR2AGT | |
| SCHEMBL9022990 | 0.82 | AGTR1 (0.48) | LTB4R2AGTR1AGTR2AGT | |
| SCHEMBL9421635 | 0.81 | AGTR1 (0.44) | LTB4R2AGTR1AGTR2HPGDALDH1A1 | |
| SCHEMBL3950208 | 0.81 | AGTR1 (0.49) | AGTR1AGTR2AGT | |
| SCHEMBL8532808 | 0.81 | AGTR1 (0.51) | AGTR1AGTR2ALDH1A1AGTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531576-B2 | Biphenyl derivatives | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1354871-B1 | BIPHENYL DERIVATIVES | POLA PHARMA INC (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | disclosed |
| US-7312340-B2 | Synthesis of 2-butyl-3-(1-trityl-1H-tetrazol-5-YL)biphenyl-4-YL)-1,3-diazaspiro[4,4]- non-ene-4-one | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-25 | — | — | US | disclosed |
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1354871-A1 | BIPHENYL DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048909-A1 | N-alkyl-N-(p-substituted-phenyl)benzylamine that is N-substituted with carbocyclic aminocarbonylalkylene, aminocarbonyl, or aminocarbonylaminosulfonyl; ACAT inhibitors; treating e.g.,hypercholesterolemia and atherosclerosis | ACAT2, LCAT, NAT1 | LTB4R2 1743/4885AGTR1 249/4885AGTR2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.